Child and Adolescent Psychiatry and Mental Health Publishes Vyvanse ADHD Data
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse® (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
Vyvanse is the first oral ADHD stimulant with published data that demonstrated significant ADHD symptom improvement from 1.5 hours up to 13 hours after administration in children, from morning through homework and family time
PHILADEPHIA – July 22, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) after administration. In this pediatric analog classroom study, treatment with Vyvanse was associated with significant improvement in behavior and attention in children at each time point measured, with improvement at 13 hours after administration.
“Pediatric patients may require ADHD symptom improvement both
at school and after school,” said Sharon Wigal, PhD, lead
investigator of the study, clinical professor of pediatrics and
director of clinical trials in the Child Development Center at the
University of California, Irvine. “These published data are
the first to have shown duration of effect of an oral ADHD
stimulant in children aged 6 to 12 at 13 hours after
administration. Physicians and caregivers who are seeking a
long-acting medication that provides ADHD symptom improvement from
morning through homework and family time may want to consider this
Vyvanse study data.”
On May 22, 2009, the US Food and Drug Administration (FDA) approved
a change to the prescribing information for Vyvanse to include
supplemental data that demonstrated significant ADHD symptom
improvement in children aged 6 to 12 from the first time point
measured (1.5 hours) up to 13 hours postdose. Vyvanse is now the
first and only oral ADHD stimulant treatment to have efficacy at 13
hours after administration for pediatric patients included in its
product labeling.
“Shire is proud to be at the forefront of ADHD research and
treatment development and is committed to providing patients with
effective ADHD medications, such as Vyvanse,” said Liza
Squires, MD, Research and Development Business Unit Leader for
Shire. “These findings provided further support that Vyvanse
can be an important treatment option for children who require
duration of ADHD symptom improvement throughout the day.”
Vyvanse Demonstrated Significant Symptom Improvement at 13 Hours
After Administration
The study was a randomized, double-blind, placebo-controlled, analog classroom study that assessed the efficacy and safety of Vyvanse in 129 children aged 6 to 12 years with ADHD. Following a four-week, open-label, dose-optimization phase with Vyvanse at 30 mg, 50 mg, and 70 mg doses, patients entered a two-week, double-blind, crossover phase where they were randomized into two groups. One group received their optimal dose of Vyvanse the first week and placebo the second week. The second group received placebo the first week and their optimal dose of Vyvanse the second week.
The primary objective of this study was to assess the time of onset
of Vyvanse compared with placebo, as measured by the Swanson,
Kotkin, Agler, M-Flynn, and Pelham Deportment
(SKAMP-D) rating scale. Secondary objectives included assessment of the duration of efficacy of VYVANSE compared with placebo, as measured by the SKAMP-D scale, and assessment of efficacy and time of onset of Vyvanse compared with placebo as measured by SKAMP Attention (SKAMP-A), and Permanent Product Measure of Performance (PERMP) scales.
In the study, Vyvanse demonstrated significant efficacy versus
placebo at 1.5 hours, the first time point measured. Further,
Vyvanse treatment was associated with significant efficacy as
measured by both subjective (SKAMP-D and SKAMP-A) and objective
(PERMP) assessments from the first time point (1.5 hours) through
the last time point (13 hours) assessed during the classroom day,
and at all time points in between (2.5, 5.0, 7.5, 10.0, and 12.0
hours).
Safety was also evaluated during the study. The adverse event profile for Vyvanse was similar to other currently marketed stimulants. The most frequently reported adverse events (greater than or equal to 10 percent) in the dose-optimization phase for patients taking Vyvanse were decreased appetite, insomnia, headache, irritability, upper abdominal pain, and affect lability.
Vyvanse, which was introduced in the United States in July 2007 for the treatment of ADHD in children aged 6 to 12 years and approved in April 2008 to treat ADHD in adults, is currently available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. To date, more than 6 million Vyvanse prescriptions have been filled, bringing the current US market share to over 12 percent based on weekly branded prescription volume. Additionally, Shire has executed agreements with 10 of Shire’s top 11 managed care organizations (MCOs) to cover Vyvanse in a preferred formulary position.
Vyvanse is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of Vyvanse to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times.
Additional information about Vyvanse and Full Prescribing
Information, including Medication Guide, are available at
www.vyvanse.com
For further information please contact:
Media
Matthew Cabrey (Shire North America)
+1 484 595 8248
Mindy Huber (Porter Novelli for Shire)
+1 212 601 8330
Notes to Editor:
The Swanson, Kotkin, Agler, M-Flynn, and Pelham Deportment (SKAMP-D) scale is a standardized, validated classroom assessment tool used for evaluating the behavioral symptoms of ADHD and higher SKAMP-D ratings reflecting greater impairment.
The Permanent Product Measure of Performance (PERMP) is an
age-adjusted collection of math problems that provides an objective
measure of performance based on the number of attempted and
completed math problems.
About VYVANSE Vyvanse is indicated for the treatment of ADHD.
Efficacy based on two controlled trials in children aged 6 to 12
and one controlled trial in adults.
Tell the doctor about any heart conditions, including structural
abnormalities, that you, your child, or a family member, may have.
Inform the doctor immediately if you or your child develops
symptoms that suggest heart problems, such as chest pain or
fainting.
Vyvanse should not be taken if you or your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.
Tell the doctor before taking Vyvanse if you or your child is being treated for or has symptoms of depression (sadness, worthlessness, or hopelessness) or bipolar disorder; has abnormal thought or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell the doctor immediately if you or your child develops any of these conditions or symptoms while taking Vyvanse.
Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.
Talk to your health care provider if your child experiences slowing of growth (height and weight). Children should have their height and weight checked periodically while taking Vyvanse. Your health care provider may stop Vyvanse treatment if a problem is found during these check-ups.
Vyvanse was generally well tolerated in clinical studies. The most common side effects reported in studies of Vyvanse were: children – decreased appetite, difficulty falling asleep, stomachache, and irritability; adult – decreased appetite, difficulty falling asleep, and dry mouth.
Aggression, new abnormal thoughts/behaviors, mania, growth
suppression, worsening of motion or verbal tics, and
Tourette’s syndrome have been associated with use of drugs of
this type. Tell the doctor if you or your child has blurred vision
while taking Vyvanse.
About ADHD
ADHD is one of the most common psychiatric disorders in children and adolescents. Worldwide prevalence of ADHD is estimated at 5.3 percent (with large variability), according to a comprehensive systematic review of this topic published in 2007 in the American Journal of Psychiatry. In the United States, approximately 7.8 percent of all school-aged children, or about 4.4 million children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the Centers for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of US adults aged 18 to 44 based on results from the National Comorbidity Survey Replication. When this percentage is extrapolated to the full US population aged 18 and over, approximately 9.8 million adults are believed to have ADHD.
ADHD is a psychiatric behavioral disorder that manifests as a
persistent pattern of inattention and/or hyperactivity-impulsivity
that is more frequent and severe than is typically observed in
individuals at a comparable level of development. The specific
etiology of ADHD is unknown and there is no single diagnostic test
for this syndrome. Adequate diagnosis requires the use of medical
and special psychological, educational and social resources,
utilizing diagnostic criteria such as Diagnostic and Statistical
Manual of Mental Disorders-IV (DSM-IV-TR) or International
Classification of Diseases 10 (ICD-10).
Although there is no “cure” for ADHD, there are
accepted treatments that specifically target its symptoms. Standard
treatments include educational approaches, psychological, or
behavioral modification, and medication.
SHIRE PLC Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the
Company’s Web site: www.shire.com
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995 Statements included herein that are not
historical facts are forward-looking statements. Such
forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, the Company’s
results could be materially adversely affected. The risks and
uncertainties include, but are not limited to, risks associated
with: the inherent uncertainty of research, development, approval,
reimbursement, manufacturing and commercialization of the
Company’s Specialty Pharmaceutical and Human Genetic
Therapies products, as well as the ability to secure and integrate
new products for commercialization and/or development; government
regulation of the Company’s products; the Company’s
ability to manufacture its products in sufficient quantities to
meet demand; the impact of competitive therapies on the
Company’s products; the Company’s ability to register,
maintain and enforce patents and other intellectual property rights
relating to its products; the Company’s ability to obtain and
maintain government and other third-party reimbursement for its
products; and other risks and uncertainties detailed from time to
time in the Company’s filings with the Securities and
Exchange Commission.
Posted: July 2009
